Brookstone Capital Management Has $24.36 Million Position in Amgen Inc. $AMGN

Brookstone Capital Management boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 74,409 shares of the medical research company’s stock after purchasing an additional 3,098 shares during the period. Brookstone Capital Management’s holdings in Amgen were worth $24,355,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund acquired a new stake in Amgen during the fourth quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter worth approximately $32,000. Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $33,000. Cloud Capital Management LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. Finally, Saranac Partners Ltd bought a new position in shares of Amgen during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AMGN shares. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research note on Tuesday, January 20th. Guggenheim upped their target price on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Daiwa Securities Group lifted their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $354.60.

Amgen Trading Up 0.1%

Shares of AMGN opened at $349.00 on Tuesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market cap of $188.14 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 3.46 and a beta of 0.45. The stock has a fifty day moving average price of $362.96 and a two-hundred day moving average price of $331.05. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the business earned $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.